Global market for acne medicine (2021 to 2030)

DUBLIN, November 25, 2021 / PRNewswire / – The report “Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030” has been added to’s offer.

Logo for research and markets

Logo for research and markets

At an estimated value of over USD 91.38 billion by 2020, the global market for acne medicine is expected to thrive with a CAGR of 3.9% and rated at over USD 14.26 billion over the forecast year 2021-2030.

Acne is the most common skin disease that is typically caused by changes in the structure of the skin. It affects nearly millions of young people across the globe. Therefore, there is a great demand for topical as well as oral acne medications. Topical medications include creams, gels and ointments consisting of retinoids, benzoyl peroxide, salicylic acid and others. On the other hand, oral acne medicine is relatively more effective where moderate to severe acne does not respond to topical remedies.

Market dynamics and trends

Several factors such as altered hormone levels, increasing teenage population and growing use of skin care products are driving the growth of the global market for acne medicine significantly. In addition, excessive production of oil from sebaceous glands and unhygienic lifestyle causes the occurrence of acne, which has a positive impact on market growth.

However, side effects such as skin irritation, dry skin and erythema or skin redness due to the use of acne medicine are expected to inhibit the growth of the market. On the contrary, increased R&D in skin care, together with the high market potential across untapped emerging markets, is expected to be opportunistic for market growth. Furthermore, the growing incidence and severity of acne is one of the most important factors that will boost the market size in the forecast period.

Market segmentations and scope of the study:

The global market share of acne medicine is segmented on the basis of therapeutic class, formulation, type, acne type, distribution channel and geography. Based on therapeutic class, the market is categorized into retinoids, antibiotics, benzoyl peroxide, salicylic acid and others. According to the wording, the market is divided into topical drugs and oral drugs. By type, the market is divided into prescription drugs and over-the-counter drugs.

Based on the type of acne, the market is divided into non-inflammatory acne and inflammatory acne. According to the distribution channel, it is categorized as retail stores, e-commerce and pharmacies and pharmacies. Geographical fragmentation and analysis of each segment includes regions that include North America, Europe, Asia and the Pacific and RoW.

Geographical analysis

In terms of geography, North America had a large share of the market in 2019. This is attributed to the increase in the use of skin care products, and increased awareness of natural acne medicine has driven the demand for acne medicine throughout this region. However, Asia-Pacific is expected to grow rapidly with increasing market size due to factors such as increased increase in healthcare costs and higher demand for acne therapy across developing countries in the region.

Competitive landscape

Maximum growth opportunities make the market for acne medicine extremely competitive. Some of the major players in the market are Almirall SA., Bausch Health Companies Inc., Galderma SA, Mayne Pharma Group Limited, GlaxoSmithKline Plc (GSK), Mylan NV, Pfizer Inc., Johnson & Johnson, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd. and many more. A number of development strategies have been adopted by companies in the last few years. For example in June 2020, Bausch Health Companies Inc. and Ortho Dermatologics, announced that ARAZLO (tazarotene) Lotion is commercially available to healthcare professionals throughout the United States.

Also in February 2020, Almirall, SA (ALM) announced the development of Seysara (sarecycline), the advanced tetracycline-derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. The product is expected to be submitted to the National Medical Products Administration (NMPA) by 2023.

Key topics covered:

1. Introduction
1.1. Report description
1.2. Who should read this report
1.3. Key market segments
1.4. Research methodology

2. Acne Medicine Market – Executive Summary
2.1. Market Snapshot, 2020 – 2030, Million Usd

3. Market overview
3.1. Market definition and scope
3.2. Market dynamics

4. Covid-19 Analysis
4.1. Impact on market size
4.2. End-user trends and preferences as well as budget and financial impact
4.3. Key player strategies to tackle Covid-19’s influence in the market

5. Market share analysis
5.1. Market share analysis of top providers of acne medicine, 2020

6. Global market for acne medicine, by therapeutic class
6.1. Overview
6.2. Retinoids
6.3. Antibiotics
6.4. Salicylic acid
6.5. Benzoyl peroxide
6.6. Others

7. Global market for acne medicine, by wording
7.1. Overview
7.2. Topical medicine
7.3. Oral medicine

Global Market for Acne Medicine, by Type
8.1. Overview
8.2. Prescription drugs
8.3. Over-the-counter medicine (Otc).

9. Global market for acne medicine, by type of acne
9.1. Overview
9.2. Inflammatory acne
9.3. Non-inflammatory acne

10. Global market for acne medicine by distribution channel
10.1. Overview
10.2. Grocery stores
10.3. Pharmacies and pharmacies
10.4. E-commerce

Global Market for Acne Medicine, by Region
11.1. Overview
11.2. North America
11.3. Europe
11.4. Asia-Pacific
11.5. The rest of the world

12. Company profiles
12.1. Almirall SA
12.2. Bausch Health Companies Inc.
12.3. Johnson & Johnson
12.4. GlaxoSmithKline plc
12.5. Galderma
12.6. Mayne Pharma Group Limited
12.7. Viatris Inc.
12.8. Sun Pharmaceutical Industries Limited
12.9. Pfizer Inc.
12.10. Teva Pharmaceutical Industries Ltd.

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, Senior Manager

For EST office hours Call + 1-917-300-0470
For US / CAN toll free call 1-800-526-8630
For GMT office hours Call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716



See original content:—by-therapeutic-class-formulation-type-acne-type-distribution- channel-and-region-301432137.html

SOURCE Research and markets

Leave a Comment